Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:UPDATE 1| Rydex Says Yes to Security Benefit Not Rated 3.2 Email Routing List Email & Route  Print Print
Thursday, June 28, 2007

UPDATE 1| Rydex Says Yes to Security Benefit

Reported by Erin Kello

Kris Robbins, CEO of Security Benefit, and the Viragh Trust, which owns Rydex Investments, have sealed their deal.

The MFWire first reported that a deal was in the works last April, (See: Rydex' Sale: Will the Best Man Win?). That the long-expected deal is finally complete became known when the two companies issued a press release Thursday morning confirming the mutual fund firm's sale. Neither party discussed the price tag on the sale, but Security Benefit spokesman, Gregg Rosenberg, tells the MFWire that it was a full sale, not just an controlling interest.

SB's Robbins championed the deal Thursday morning, explaining that it "strengthens our overall fundamentals that support continued growth in our expanding global investment business."

"The combination of Security Benefit and Rydex Investments leverages an existing successful relationship into a catalyst for broader solutions, through, sophisticated asset and risk management skills, comprehensive products options and choices and an ever-widening array for traditional and non-traditional capabilities," Robbins said.

SB's top executives were in the air Thursday morning and unavailable for follow up comments.

Kris Robbins
Security Benefit Group of Companies
CEO
Prior to the Rydex deal, the former Providian M&A pro had doubled Security Benefit's size, growing its assets under management (AUM) to $15 billion from 1998 to 2000.

Put together, the two asset managers will control roughly $35 billion in assets under management and $52 billion of assets under administration at closing.

According to fund industry insiders, this is not the first fund firm that SB has looked at buying.

Rydex was founded in 1993 by Skip Viragh, with a vision of giving more power to the investor. Viragh started with only two employees and one fund, the Rydex Nova Fund. Today Rydex has more that 80 mutual and exchange-traded funds in its line-up.

Viragh passed away in 2003 from after a battle with pancreatic cancer. After Viragh's death, Rydex was inherited by his trust, which is run by his siblings, according to industry sources.

Last fall those family members began the sale process by retaining Goldman Sachs as a banker.

Since then there have been many rumored buyers for the company with a price tag somewhere between $400 and $600 million.

The lawyers advising Security Benefit in the deal are Debevoise & Plimpton. The Debevoise team is led by partner Robert F. Quaintance, Jr.

Though it is now a part of Security Benefit, Rydex's CEO, Carl Verboncoeur and the management team will retain their positions. The company will also continue operating from its Rockville, Maryland home as a new and separate line of business.

Verboncoeur was upbeat about the sale and Rydex's role as one of Security Benefit's holdings.

"Rydex will benefit from Security Benefit's proven, well-developed and expanding distribution platforms to accelerate new business development and growth," said Verboncoeur. "With their resources and market place competence, this partnership will enable us to expand our business while retaining our competency for innovation and our focus on institutional style investment products for clients."

Earlier, the MFWire reported that the finalists in the bidding were Man Group, IXIS, GTCR Golder Rauner, a Chicago-based private equity firm, and Invesco. Published reports also named E*trade as a finalist in the auction. However, no source familiar with the sales process named E*trade as one of the bidders in interviews with the MFWire

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

3.2
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2024: Q2Q1
2023: Q4Q3Q2Q1
2022: Q4Q3Q2Q1
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly


  1. WE Boston - Women's Initiative Joint Spring Networking Reception, May 15
  2. MFDF In Focus: Making Sense of ESG - A Morningstar Guide, May 16
  3. SEC IM 2024 Conference on Emerging Trends in Asset Management, May 16
  4. ALFI Roadshow to the USA, May 16
  5. 2024 ICI Leadership Summit, May 21-23
  6. MFDF webinar - Mutual Fund Director Compensation: the MPI Annual Survey (2024), May 21
  7. Schwab Institutional Investor Day, May 22
  8. MFDF Conference of Fund Leaders Forum, June 5
  9. MFDF in-person outreach: Continuing Regulatory Impacts on Fund Boards, June 11
  10. MFDF webinar - Digital Assets in the Fund Space (Part 1 of 2), June 12
  11. 2024 MMI Leadership Pathway Seminar, Jun 12-14
  12. 2024 Nicsa Fearless Leadership Symposium, June 12
  13. MFDF webinar - Lessons Learned from the Regional Bank Volatility and the Impact on Registered Funds, June 18
  14. MFDF Director Discussion Series - Open Forum (Philadelphia), June 20
  15. New York YPEM Cornhole Classic, June 25
  16. Morningstar Investment Conference Conference 2024, Jun 26-27
  17. MFDF webinar - Mid-Year Tax Update for Registered Investment Companies, July 16
  18. MFDF Director Discussion Series - Open Forum via Zoom, July 17
  19. MFDF Director Discussion Series - Open Forum (New York), July 23
  20. 2024 MMI Annual Conference, Oct 15-17
  21. 5th Annual ETFGI Global ETFs Insight Summit, October 29
  22. MFDF webinar - Digital Assets in the Fund Space (part 2 of 2), November 7
  23. MFDF 2025 Directors' Institute, January 27 - 29, 2025
  24. MFDF 2025 Fund Governance & Regulatory Insights Conference, March 6 - 7, 2025




©All rights reserved to InvestmentWires, Inc. 1997-2024
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use